COMMUNIQUÉS West-GlobeNewswire

Syapse Announces Collaboration with Pfizer in Oncology Precision Medicine Focused on Outcomes Research Using Real-World Evidence
23/07/2019
Pfizer will work with Syapse and its network of health system partners to generate insights from real-world evidence to advance cancer outcomes research SAN FRANCISCO, July 23, 2019 (GLOBE NEWSWIRE) -- Syapse, a company [...]
Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose
23/07/2019
SANTA MONICA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has [...]
Neuronetics to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call
23/07/2019
MALVERN, Pa., July 23, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life [...]
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019
23/07/2019
SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes [...]
VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 6, 2019
23/07/2019
CAMPBELL, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2019 after the market close on [...]
Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer
23/07/2019
EXTON, Pa., July 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion of John J. Kirby to [...]
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
23/07/2019
Primary efficacy endpoint met with 71.2% response rate (p < 0.0001); women experienced, on average, an 84.3% reduction in menstrual blood loss (p < 0.0001) Achieved six key secondary endpoints including reduction [...]
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
23/07/2019
Second proof-of-concept study for IV ganaxolone with clinically meaningful activity Ganaxolone IV and oral formulations were safe and well-tolerated Future development in severe depressive disorders will focus on IV [...]
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
23/07/2019
SOUTH SAN FRANCISCO, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to [...]
BioCryst to Report Second Quarter 2019 Financial Results on August 6
23/07/2019
RESEARCH TRIANGLE PARK, N.C., July 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2019 financial results on Tuesday, August 6, [...]
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
23/07/2019
– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – BOSTON, July 23, 2019 [...]
Axogen, Inc. to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6, 2019
23/07/2019
ALACHUA, Fla., July 23, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced [...]
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
23/07/2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV [...]
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
23/07/2019
WATERTOWN, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]
RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights
23/07/2019
Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia ® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019 Preparations [...]
ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board
23/07/2019
Renowned Cancer Researcher to Support Ongoing Clinical Studies to Further Demonstrate the Safety and Efficacy of NAD+ LOS ANGELES, July 23, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it has [...]
BriaCell Announces $350,000 Equity Investment by Board of Directors
23/07/2019
BERKELEY, Calif. and VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company [...]
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
23/07/2019
VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies [...]
RadNet, Inc. Announces Date of its Second Quarter 2019 Financial Results Conference Call
23/07/2019
LOS ANGELES, July 23, 2019 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]

Pages